Скачать или смотреть SGLT-2 Inhibitors Slash AKI Risk After Cardiac Surgery – New Study Findings

SGLT-2 inhibitors, dapagliflozin, acute kidney injury, cardiac surgery, perioperative treatment.
Discover how sodium-glucose cotransporter-2 inhibitors like dapagliflozin can prevent acute kidney injury following cardiac surgery.
Up to 50% of patients undergoing cardiac surgery face AKI, but new research from the MERCURI-2 trial shows promising results.
This multicenter, randomized controlled trial involved 784 patients and found a 25% absolute reduction in AKI incidence with dapagliflozin compared to placebo.
Key outcomes: 28% AKI in dapagliflozin group vs. 53% in placebo, with significant reductions across AKI stages.
Presented at the American Society of Nephrology Kidney Week 2025, this study highlights perioperative SGLT-2 inhibition as a renoprotective strategy.
Learn about the trial design, patient demographics, and implications for cardiac surgery patients.
For nephrology enthusiasts and medical professionals, this video breaks down the evidence on SGLT-2 inhibitors preventing AKI.
Stay updated on the latest in kidney health and cardiovascular care with this in-depth analysis.